Study identifier:AZ-RU-00002
ClinicalTrials.gov identifier:NCT06057064
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)
COVID-19, SARS-CoV-2
Phase 2
No
-
All
116
Interventional
18 Years - 99 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention
Verified 01 May 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: Placebo Single dose of Placebo IM (0.9% sodium chloride) | Biological/Vaccine: Biological: Placebo Single dose of Placebo IM (0.9% sodium chloride) |
Experimental: AZD3152 Single dose of 300 mg IM | Biological/Vaccine: Biological: AZD3152 300 mg single dose of AZD3152 IM |